Purpose: To analyze the outcomes of patients treated for solitary plasmacytoma with definitive radiotherapy (RT). Material and Methods: Thirty-two patients with solitary plasmacytoma of bone (SPB; 22 patients) and extramedullary plasmacytoma (EMP; 10 patients) were treated between 1963 and 2006. The median RT dose was around 42.7 Gy (range, 15-54 Gy) over a median of 25 fractions (range, 1-32 fractions). No patient received adjuvant chemotherapy. Median follow-up was 10.1 years (range, 1-33 years). Median follow-up on living patients was 7.3 years (range, 2.1-33 years). Results: The 10-year local-control rate after RT was 87%. All 4 patients who developed a local recurrence had SPBs Ն5 cm. The 10-year multiple myeloma-free survival rates were: SPB, 30%; EMP, 90%; and overall, 50%. Progression to multiple myeloma occurred at a median of 25.1 months after RT. The 10-year overall and cause-specific survival rates were 65% and 77%, respectively. The 10-year cause-specific survival rate was 65% for patients with SPB versus 100% for those with EMP (P ϭ 0.006). Conclusion: Moderate dose RT results in a high rate of local control. Patients with SPB are more likely to progress to multiple myeloma, which adversely affects their survival compared with those with EMP.
S olitary plasmacytoma is a rare malignant neoplasm of plasma cells accounting for 5% to 10% of all plasma cell dyscrasias. [1] [2] [3] [4] The diagnosis of solitary plasmacytoma requires a single lesion composed of monoclonal plasma cells without evidence of systemic disease, such as bone marrow involvement, evidence of systemic amyloidosis, hypercalemia, end organ damage (ie, renal insufficiency), or multiple sites of involvement on comprehensive imaging. 4 Because multiple myeloma is exceedingly more common than solitary plasmacytoma, an exhaustive evaluation is required to establish a solitary site of involvement and rule out systemic disease. 1, 4 Solitary plasmacytoma of bone (SPB) and extramedullary plasmacytoma (EMP) belong to the broader diagnosis of solitary plasmacytomas, but have distinct characteristics at presentation. 1, 5, 6 SPBs are more common, most frequently involve the axial skeleton, and present with bone pain, pathologic fractures, and/or neurologic compromise. 1, 7, 8 EMPs are roughly one-third as common as SPBs and about 80% present in the upper aerodigestive tract, with nasal cavity, paranasal sinuses, and nasopharynx being the most common sites of involvement. 1, 9 Approximately 15% to 20% of patients will present with regional lymph node involvement. 1, 10, 11 Other rare sites of involvement in decreasing frequency include the gastrointestinal tract, urogenital tract, skin, lungs, breast, conjunctiva, and retroperitoneum. 9 Progression to multiple myeloma varies significantly between these 2 diagnoses. Approximately two-third of pa-tients with SPB will eventually progress to multiple myeloma, compared with roughly one-third of patients with EMP. 1, 2, 5, 7, 12, 13 Radiation therapy (RT) has been used effectively to treat patients with solitary plasmacytoma with a local control rate of over 80% observed in patients treated with moderate radiation doses (40 -50 Gy). 1, 2, 5, 6, 8, 14, 15 Progression to multiple myeloma remains common in patients with SPB despite excellent local control. The role of chemotherapy in the treatment of solitary plasmacytoma is not clearly defined, but most centers reserve chemotherapy for patients with progressive disease. 1 Given the rarity of solitary plasmacytoma, prospective data are sparse, and most of the information available regarding optimal treatment and outcomes are found in single or multi-institutional retrospective series. This is an update on the University of Florida experience treating patients with solitary plasmacytoma with RT and includes long-term follow-up and assessment of prognostic factors.
METHODS

Patients
The records of 122 patients with a diagnosis of plasma cell neoplasm (nonmultiple myeloma) were reviewed in this Institutional Review Board-approved outcomes study. All patients were treated at the University of Florida, Department of Radiation Oncology between January 1, 1963, and September 1, 2006, yielding a minimum planned follow-up of 2 years. The observed follow-up was shorter in some patients because patients who died before 2 years of follow-up were not excluded. Of the 122 patients, 32 were identified as having solitary plasmacytoma based on the following criteria: (1) a single biopsyconfirmed lesion of neoplastic-appearing plasma cells; (2) no clinical or radiographic evidence secondary sites of disease; either a skeletal survey or bone scan were required for the radiographic evaluation; (3) bone marrow biopsy with less than 10% plasma cells; and (4) absence of hypercalcemia, significant cytopenia, renal dysfunction, prior treatment for plasma cell neoplasm, or second malignancy. Patients with elevated immunoglobulin (Ig) levels, abnormal serum protein electrophoresis (SPEP), or urine protein electrophoresis (UPEP) were not excluded.
Patients were excluded for the following reasons: 59 patients had radiographic evidence of multiple myeloma at the time of diagnosis (2 or more sites of involvement); 14 patients were found to have multiple myeloma on bone marrow biopsy despite radiographic evidence of solitary lesions; 8 patients did not undergo a complete radiographic work-up; 5 patients did not undergo bone marrow biopsy; 1 patient had prior surgery and RT for solitary plasmacytoma; 1 patient had a diagnosis of plasma cell granuloma; 1 patient had a diagnosis of Waldenstrom's magroglobulinemia; and 1 patient did not undergo RT. Table 1 shows the patient characteristics by tumor type. Sites of involvement for 22 patients with SPB were as follows: spine (8 patients), pelvis/sacrum (6 patients), clavicle/scapula (3 patients), sternum/ribs (2 patients), skull (2 patients), and mandible (1 patient). Nine of 10 patients with EMP had lesions located in the upper aerodigestive tract involving the following subsites: nasopharynx (2 patients), nasal cavity (2 patients), paranasal sinuses (2 patients), tonsil (1 patient), vallecula (1 patient), and hypopharynx (1 patient). Two patients with EMP presented with a concurrent cervical lymph node metastasis. The remaining patients presented with a positive supraclavicular lymph node with no evidence of extranodal disease at the time of diagnosis. Tumor size was based on radiographic evaluation or endoscopy in the case of mucosal EMP and was broadly classified as Ͻ5 cm or Ն5 cm. Nineteen patients (59%) had lesions Ն5 cm (SPB, 15 of 22; EMP, 4 of 10). Pretreatment radiographic evaluation included any combination of the following modalities (most patients underwent multiple studies): skeletal survey (25 patients),; bone scan (21 patients), computed tomography (CT) of the chest, abdomen, and pelvis (11 patients); spine magnetic resonance imaging (MRI, 7 patients); and whole-body positron emission tomography (PET, 1 patient). All patents were evaluated with SPEP and/or quantitative Ig (usually by immunofixation, but the exact methodology varied with the era of treatment). Seventeen patients had abnormal SPEPs or abnormally elevated Igs at presentation. Twenty-five patients were evaluated with UPEP, which was positive in 1 patient on presentation. Normal values for all tests were those reported by the laboratory at the time of assessment.
Treatment
Seven patients (22%) underwent a surgical procedure other than biopsy before RT: complete resection (3 patients), partial resection (3 patients), and not specified (1 patient). The remaining 25 patients were treated with RT alone. Patients received once-daily fractions of RT to a median dose of 42.7 Gy (range, 15-54 Gy) over a median of 25 fractions (range, 1-32 fractions). The median length of treatment was 34 days (range, 1-46 days). RT techniques and beam energies varied by tumor location and were consistent with accepted standards at the time of treatment. One patient with an SPB involving the L2 vertebra was treated with a single 15-Gy fraction under our spine stereotactic body radiation therapy protocol. Six patients received cervical nodal irradiation. Four patients were irradiated electively and 2 patients had clinically positive lymph nodes at the time of diagnosis. No patient received adjuvant chemotherapy.
Follow-up and Observed Outcomes
All patients underwent routine follow-up evaluations to assess clinical response, progression to multiple myeloma, and treatment complications at approximately 1 month after completing RT, then every 3 months for 2 years, with gradually decreasing fre-quency thereafter. Often, patients were evaluated more frequently by multiple specialties at our institution. All follow-up included a history and physical examination. Follow-up imaging was performed at the treating physicians' discretion. Evaluations with SPEP, UPEP, and quantitative immunoglobulin (Ig) levels were performed on all patients who initially presented with abnormal test results; otherwise they were at the clinicians' discretion. Follow-up bone marrow biopsy was performed when clinically indicated.
The observed outcomes were local control (LC), multiplemyeloma-free survival (MMFS), overall survival (OS), and causespecific survival (CSS was defined as death with recurrent or progressive disease). Radiographically persistent but stable lesions were considered locally controlled. Local progression and/or development of a new lesion within or adjacent to the treatment field were considered local failures. Radiographic evidence of new myeloma lesions (ie, lytic lesions or pathologic fractures outside the treatment field), and/or development of bone marrow plasmacytosis over 10% constituted progression to multiple myeloma. Evidence of persistent or increasing abnormalities on SPEP or Ig levels did not constitute recurrent disease or progression to multiple myeloma without the presence of new radiographic findings, pathologic fractures, or bone marrow involvement. However, these findings were used to guide further evaluation.
Management at the time of progression included observation, chemotherapy, additional RT with or without chemotherapy, or marrow ablative therapy with stem cell transplantation. Salvage treatment was offered at the discretion of the treating physician(s) at the time of progression, and was not evaluated for this manuscript. All patients who progressed to multiple myeloma and subsequently died were considered "died with disease present" (DWD).
Statistical Analysis
All statistical computations were accomplished with SAS and JMP software (SAS Institute, Cary, NC). The Kaplan-Meier product limit method provided estimates of local control, freedom from multiple myeloma progression, overall survival, and cause-specific survival. 16 For each end point, detection of statistically significant differences between strata of selected prognostic factors was accomplished with the log-rank test statistic. 
RESULTS
Follow-up
Local Control
Local control was observed in 28 of 32 patients (88%). Actuarial local control rates for all 32 patients at 5 and 10-years were both 87%. Local recurrences occurred 0.9, 8.8, 13.0, and 24.7 months after completing RT. Tumor type (SPB vs. EMP, P ϭ 0.167; Fig. 1 ), post-RT abnormal SPEP (P ϭ 0.079), and elevated Igs (P ϭ 0.120) were not significant predictors for local control on univariate analysis ( Table 2 ). All 4 local recurrences were observed in patients with SPBs with tumors Ն5 cm in maximum diameter; however, there were too few local recurrences for tumor size to reach statistical significance (P ϭ 0.09). Patients with local recurrences received RT doses ranging from 30.4 to 45 Gy, which did not differ from patients without local recurrences. Three of the 4 local recurrences were observed in pelvic or sacral tumors with the fourth 
Progression to Multiple Myeloma
Progression to multiple myeloma was observed in 17 of the 32 patients (53%). Actuarial MMFS rates for all 32 patients at 5 and 10-years were 58% and 50%, respectively. Progression to multiple myeloma was significantly higher for patients with SPB versus EMP (Fig. 2) . Fifteen of the 22 patients (68%) with SPB eventually progressed to multiple myeloma, whereas only 2 of 10 patients (20%) with EMP progressed to multiple myeloma. The 10-year MMFS rates for SPB and EMP were 30% and 90%, respectively (P ϭ 0.009). One patient with EMP had late progression to multiple myeloma occurring over 12 years after completing RT. Other variables such as tumor size (P ϭ 0.25), post-treatment abnormalities in SPEP (P ϭ 0.19), or Ig levels (P ϭ 0.99) did not significantly affect MMFS on univariate analysis ( Table 2 ). Tumors of the head and neck did not progress to multiple myeloma as frequently as other sites of disease; however, all but 3 lesions in the head and neck were extramedullary plasmacytomas. Progression to multiple myeloma occurred at a median of 25.1 months after completing RT (range, 1.8 -164.9 months). Seven (41%) of patients who progressed to multiple myeloma did so within the first year of observation after completion of RT.
Survival
Ten patients were alive at the time of analysis. Five-and 10-year actuarial OS rates for all 32 patients were 87% and 65%, respectively. CSS was observed to be 90% and 77% at 5 and 10-years, respectively. Both OS and CSS varied significantly by tumor type (Figs. 3, 4) . For SPB patients, the 10-year OS and CSS rates were 55% and 65%, respectively, which were significantly lower than the 10-year OS and CSS rates for EMP, which were 80% and 100%, respectively (OS, P ϭ 0.018; CSS, P ϭ 0.006). On univariate analysis, tumor size, or post-treatment abnormalities in SPEP or Ig levels were not significant prognostic factors for OS or CSS ( Table 2 ).
Toxicity
Treatment was tolerated with few complications. One patient with EMP involving the nasopharynx experienced severe mucositis requiring a brief treatment break on the 13th day of RT. Another patient with EMP of the maxillary sinus experienced serous otitis 
DISCUSSION
Our series showing excellent local control with moderate doses of RT is comparable to other retrospective series that have reported local control rates ranging between 78% and 100% (Table  3) . 2, 6, 8, [12] [13] [14] [15] 17 In the current study, there was a nonsignificant trend toward decreased local control at 5 years with tumors Ն5 cm in diameter. The association of decreased local control with increased tumor size has been inconsistent throughout the literature. Tsang et al reported on 46 patients with solitary plasmacytoma (SPB, 32; EMP, 14) treated with RT and found that the 8-year local control rate was 100% for tumors Ͻ5 cm as compared with 38% for tumors Ն5 cm in diameter (P Ͻ 0.01). 6 However, in a multicenter retrospective study of 258 patients treated mostly with RT alone throughout Europe, there was no significant difference in the likelihood of local control with increased tumor size. Local control at 10-years was 87% versus 78% for tumor Ͻ5 cm and Ն5 cm, respectively (P ϭ 0.41). 15 In a Turkish multicenter retrospective study, Kilciksiz et al reported the results of 80 patients (SPB, 57; EMP, 23) treated with RT (38 treated postoperatively) and showed that increasing tumor size was not associated with decreased local control. For patients with Ն5 cm tumor, the 10-year local control rate was 96% compared with 88% for tumors Ͻ5 cm in diameter (P ϭ 0.34). 18 In our current study, dose did not influence the probability of local control. The 4 local failures occurred in patients receiving doses ranging between 30.4 and 45 Gy, which did not differ from patients who did not experience a local recurrence. Tsang et al also showed that doses of Ͻ30 Gy, between 30 and 40 Gy, or Ͼ40 Gy did not result in different local control rates. 6 In 86 patient with EMP of the head and neck, RT doses Ͻ30 Gy did not result in significantly lower local control. 17 Ozsahin et al also showed no significant dose-response relationship among 244 patients treated with RT. After adjusting the RT dose to a biologically equivalent dose of 2 Gy per fraction, no dose-response relationship was observed for doses Ͻ30 Gy, 30 to 40 Gy, 40 to 50 Gy, or Ͼ50 Gy. 2 Others have shown that in secretory disease, an increased dose of RT Ͼ45 Gy did not resolve elevated m-spikes. 6 Alternatively, in a French study of 17 patients with EMP treated with RT, doses Ͼ45 Gy resulted in a significantly greater 5-year local control rate of 100% versus 50% for doses Ͻ45 Gy (P ϭ 0.034). 19 The poor local control rate observed at lower radiation doses in this trial has not been reported elsewhere.
In this series, all 3 patients who underwent complete resection before radiation therapy remained locally controlled at last followup. There were too few patients to assess the prognostic significance of surgical resection on local control. Surgical resection was performed in most cases before establishing a histologic diagnosis. In other cases, surgery was performed to stabilize pathologic fractures.
Progression to multiple myeloma remains the biggest challenge in the management of solitary plasmacytoma. It is observed in most cases of SPB and less frequently seen in patients with EMP, indicating that these are likely 2 distinct pathologic entities. 1, 5, 20 Tsang et al reported 8-year MMFS rates of 36% and 84% for SPB and EMP, respectively (P ϭ 0.007). 6 Similarly, Ozsahin et al reported 10-year MMFS rates of 64% for 52 patients with EMP and 38% for 206 patients with SPB (P ϭ 0.0009). 2 Among 46 patients with solitary plasmacytoma treated at Mallinckrodt Institute (St. Louis, MO), 36% of patients with EMP compared with 53% of patients with SPB progressed to multiple myeloma. 7 A review of the literature reveals that the median time to progression to multiple myeloma ranges from 13 to 31 months. 1, 2, 7, 12, 14 In our analysis, posttreatment abnormal SPEP or Ig levels were not significantly associated with progression to multiple myeloma. Similarly, no relationship between persistent abnormalities on SPEP and progression to multiple myeloma was observed among the 46 patients treated at Mallinckrodt, 7 and 46 patients treated at the Princess Margaret Hospital (Toronto). 6 However, data from the MD Anderson Cancer Center (Houston, TX) showed that in patients with SPB, 17 of 30 (57%) patients with a persistently elevated m-spike progressed to multiple myeloma, whereas, only 2 of 11 patients (18%) who had resolution of the m-spike progressed (P ϭ 0.004). 12 Further analysis of the M.D. Anderson series showed that persistence of myeloma protein for more than 1 year after RT was a significant predictor of poor MMFS. 21 Other prognostic factors for progression to multiple myeloma, such as age and tumor size, have also been reported. 6 In the current study, progression to multiple myeloma within 1 year after completing RT was common, occurring in 46% of patients with progressive disease. Early progression may indicate the presence of occult disease at diagnosis. It has been posited that with more sophisticated imaging modalities such as MRI and PET, some patients with SPB will be upstaged to multiple myeloma, allowing for better selection of patients who can be treated with RT alone. [22] [23] [24] Moulopoulos et al reported on the use of spinal MRI to stage solitary plasmacytoma and showed that 4 of 12 patients (33%) were upstaged to multiple myeloma with the addition of MRI. 22 In a series of patients with SPB from M.D. Anderson, 6 of 7 patients whose work-up included a spinal MRI did not progress to multiple myeloma, whereas only 1 of 8 patients who were staged without MRI remained free from progression to multiple myeloma. 13 In the current series this trend was not observed. Seven patients underwent pretreatment MRI, with 5 eventually progressing to multiple myeloma. Of those who progressed, 2 of 5 did so within 1 year of completing RT.
The role of chemotherapy in the initial management of solitary plasmacytoma has not been defined. A single-institution randomized controlled trial from Mexico examined the role of RT followed by maintenance melphalon/prednisone (every 6 weeks for 3 years) compared with RT alone. With a median follow-up of 8.9 years, 22 of 25 patients (88%) receiving maintenance chemotherapy remained alive without progression to multiple myeloma compared with 13 of 28 patients (46%) receiving RT alone (P Ͻ 0.01). 13 In multiple retrospective series, adding chemotherapy to RT did not result in improved MMFS. 2, 6, 15 However, the regimens employed were variable and not standardized.
Major and minor criteria have been proposed for the diagnosis of multiple myeloma. A histologically confirmed plasmacytoma (major criterion) and the presence of abnormal myeloma protein (minor criterion) suffice to establish the diagnosis of stage I multiple myeloma. 25 Patients with solitary plasmacytoma may present with abnormalities on SPEP and fit into this latter catergory. Others will have abnormal Ig levels or mild elevation in bone marrow plasmacytosis. Some have occult disease at diagnosis and others will likely progress. With recent advances in molecular diagnostic techniques, we may at some point be able to more accurately identify which patients are at risk for disease progression. Regardless, the current study and others have shown that RT, either definitively or postoperatively, will result in a substantial percentage of patients with durable MMFS. Rates of 30% to 48% at 5 and 10-years have been observed. 1, 2, 7, 12, 14 These percentages will likely increase with improved detection of occult disease, allowing for better selection of patients for RT.
This update on the University of Florida experience with solitary plasmacytoma treated with RT did not include 15 patients previously reported on by Bolek et al 5 Patients from this earlier report were excluded from this analysis for either incomplete documentation of radiographic work-up, lack of bone marrow biopsy, elevated bone marrow plasmacytosis, or secondary lesions noted at time of diagnosis.
Our current treatment recommendation at the University of Florida is to treat histologically confirmed solitary plasmacytoma, after an exhaustive search for systemic disease, with definitive RT to doses of 40 to 45 Gy at 1.8 Gy daily fractions. We do not include chemotherapy as part of the planned therapy. We use IMRT to treat mucosal lesions of the head and neck when it can spare a significant amount of normal tissue. We include elective nodal irradiation to the appropriate lymphatic sites for all patients with head and neck mucosal extramedullary plasmacytoma. 
